Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Historic benchmarks for either chemotherapy agent alone are 23% ORR ... a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in patients with non-small ...

Historic benchmarks for either chemotherapy agent alone are 23% ORR ... a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in patients with non-small ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

This expansion aims to evaluate the efficacy of THIO both in combination with Libtayo® and as a standalone treatment ... which is promising compared to typical outcomes with standard chemotherapy.

We had the phase 3 HARMONi trial [NCT06396065], which is an ivonescimab plus chemotherapy trial that enrolled very quickly and is now being read out. We have a trial [NCT05704634] of an IL-6 [receptor ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...